Lam Research (NASDAQ:LRCX) Raised to Positive at Susquehanna

Lam Research (NASDAQ:LRCX) was upgraded by stock analysts at Susquehanna from a “neutral” rating to a “positive” rating in a research note issued on Thursday,Briefing.com Automated Import reports. The brokerage currently has a $125.00 price objective on the semiconductor company’s stock, up from their previous price objective of $75.00. Susquehanna’s price objective suggests a potential upside of 42.60% from the stock’s current price.

Several other equities analysts have also weighed in on LRCX. Wolfe Research lowered shares of Lam Research from an “outperform” rating to a “peer perform” rating in a research report on Wednesday, January 15th. The Goldman Sachs Group lowered their price target on shares of Lam Research from $96.00 to $85.00 and set a “buy” rating on the stock in a research report on Friday, January 10th. Stifel Nicolaus reiterated a “buy” rating and set a $100.00 price objective (down from $105.00) on shares of Lam Research in a research note on Thursday, October 24th. Needham & Company LLC reiterated a “buy” rating and set a $90.00 price objective on shares of Lam Research in a research note on Thursday, January 30th. Finally, Sanford C. Bernstein upgraded shares of Lam Research from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $85.00 to $91.00 in a research note on Thursday, January 30th. Six equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $97.72.

Lam Research Trading Up 1.2 %

Shares of LRCX opened at $87.66 on Thursday. The stock has a 50 day simple moving average of $78.00 and a 200-day simple moving average of $77.90. Lam Research has a 1 year low of $68.87 and a 1 year high of $113.00. The stock has a market cap of $112.53 billion, a PE ratio of 26.63, a PEG ratio of 1.43 and a beta of 1.46. The company has a current ratio of 2.54, a quick ratio of 1.73 and a debt-to-equity ratio of 0.51.

Lam Research (NASDAQ:LRCX) last issued its quarterly earnings data on Wednesday, January 29th. The semiconductor company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.87 by $0.04. Lam Research had a net margin of 26.49% and a return on equity of 51.86%. On average, sell-side analysts predict that Lam Research will post 3.71 EPS for the current fiscal year.

Institutional Trading of Lam Research

Several hedge funds have recently bought and sold shares of LRCX. Financial Perspectives Inc grew its position in Lam Research by 908.8% in the 4th quarter. Financial Perspectives Inc now owns 343 shares of the semiconductor company’s stock valued at $25,000 after purchasing an additional 309 shares during the period. Fairway Wealth LLC boosted its holdings in shares of Lam Research by 900.0% in the 4th quarter. Fairway Wealth LLC now owns 340 shares of the semiconductor company’s stock worth $25,000 after buying an additional 306 shares during the last quarter. Atwood & Palmer Inc. purchased a new position in shares of Lam Research in the 4th quarter worth about $27,000. Midwest Capital Advisors LLC purchased a new position in shares of Lam Research in the 4th quarter worth about $27,000. Finally, West Paces Advisors Inc. purchased a new position in shares of Lam Research in the 4th quarter worth about $27,000. Institutional investors and hedge funds own 84.61% of the company’s stock.

Lam Research Company Profile

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products.